⌘K
t
| Date | 9 Nov 2021 |
| Time | 07:00:03 |
| Category | Board changes |
| ID | 7253R |
9 November 2021
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that Dr Alastair Riddell, currently Non-Executive Chairman, will assume the role of Executive Chairman with effect from 1 December 2021.
Enquiries:
|
Nuformix plc |
via Walbrook |
||||
|
Dr Alastair Riddell, Non-Executive Chairman |
|
||||
|
Dr Anne Brindley, CEO |
|
||||
|
|
|
||||
|
Allenby Capital Limited |
+44 (0) 20 3328 5656 |
||||
|
Nick Athanas / George Payne (Corporate Finance) |
|
||||
|
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) |
|
||||
|
|
|
||||
|
Walbrook PR |
[email protected] or +44 (0)20 7933 8780 |
||||
|
Anna Dunphy / Phillip Marriage |
Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082 |
||||
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.